# Cytomegalovirus (CMV) Vaccine in Donors and Recipients Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)

> **NCT00285259** · PHASE2 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 112 (actual)

## Conditions studied

- Acute Lymphoblastic Leukemia
- Chronic Myelogenous Leukemia
- Acute Myelogenous Leukemia
- Hodgkin's Lymphoma
- Non-Hodgkin's Lymphoma
- Myelodysplastic Syndrome

## Interventions

- **BIOLOGICAL:** VCL-CB01
- **OTHER:** Phosphate-buffered Saline (PBS)

## Key facts

- **NCT ID:** NCT00285259
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01-31
- **Primary completion:** 2009-11-30
- **Final completion:** 2010-11-30
- **Target enrollment:** 112 (ACTUAL)
- **Last updated:** 2024-10-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00285259

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00285259, "Cytomegalovirus (CMV) Vaccine in Donors and Recipients Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00285259. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*